Unicycive Therapeutics
UNCY
30 hedge funds and large institutions have $27.4M invested in Unicycive Therapeutics in 2025 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 9 increasing their positions, 1 reducing their positions, and 3 closing their positions.
800% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 1
333% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 3
50% more funds holding
Funds holding: 20 → 30 (+10)
11% more capital invested
Capital invested by funds: $24.6M → $27.4M (+$2.8M)
5.1% less ownership
Funds ownership: 40.69% → 35.59% (-5.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
+$2.85M |
| 2 |
Squarepoint
New York
|
+$511K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$292K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$231K |
| 5 |
Goldman Sachs
New York
|
+$197K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$104K |
| 2 |
Renaissance Technologies
New York
|
-$56.2K |
| 3 |
Lazard Asset Management
New York
|
-$55K |
| 4 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$12.7K |
UNCY Hedge Fund Activity: Q3 2025 in Review
30 of the 7,645 institutional investors tracked by Wall St. Rank reported a position in Unicycive Therapeutics (UNCY) for Q3 2025, worth a combined $27.4M — up 11% from $24.6M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new UNCY positions and 3 closed out — a net gain of 10 holders — while 9 added to existing stakes and 1 trimmed.
The largest buyer was Vivo Capital, adding an estimated $2.85M. The largest seller was JP Morgan Chase, exiting entirely with an estimated $104K sold.
- 30 institutional investors held Unicycive Therapeutics (UNCY) as of Q3 2025, up from 20 in Q2 2025.
- Funds reported $27.4M of Unicycive Therapeutics stock for Q3 2025, up 11% quarter-over-quarter.
- 13 funds opened new Unicycive Therapeutics positions in Q3 2025 and 3 closed out, a net change of +10 holders.
- The largest Unicycive Therapeutics buyer in Q3 2025 was Vivo Capital, an estimated $2.85M added.
- The largest Unicycive Therapeutics seller in Q3 2025 was JP Morgan Chase, an estimated $104K sold.
Based on aggregated 13F filings for Q3 2025.